In this interview, we talk to Mary Lame (Principal Applications Scientist, Waters Corporation; MA, USA) who discusses the key challenges scientists face when developing robust peptide bioanalytical assays.
In this interview, Ils Pijpers (Janssen R&D) discusses the challenges faced with sample preparation and method validation when using high-resolution mass spectrometry.
In this interview, Jon Haulenbeek (Bristol-Myers Squibb; NJ, USA) discusses his role as a Group Leader running the Reagent Center of Excellence in the Translational Medicine Division.
In this interview, John Kadavil (US FDA; MA, USA) shares his thoughts on the draft ICH M10 guidance for bioanalytical method validation, indicating how this will change the bioanalytical regulatory landscape.
In this interview, Eric Woolf (Merck; PA, USA) provides an overview of the draft ICH M10 guidance for bioanalytical method validation, indicating why there is a need for new guidance despite many BMV guidance currently being available.
In this interview, Hanna Ritzén (Mercodia; Uppsala, Sweden) provides an insight into her recent article on classification of commercial LBA kits for biomarkers, and why this area of bioanalysis is important.
In this interview, Wenying Jian (Janssen Research & Development, Johnson & Johnson; NY, USA) describes the basic principles of hybrid LBA/LC–MS and how this technique can be used to quantify proteins.
Hear more about the recent mass spectrometry product launches from SCIEX announced at ASMS 2019, including the new Acoustic Ejection Mass Spectrometry technology, in this interview with Neil Walsh (SCIEX; MA, USA).
In this interview, Zamas Lam (QPS; DE, USA) discusses various methods that can be used to quantify oligonucleotide drugs and the progress that has been made to regulate and standardize oligonucleotide analysis in recent years.
In this interview, Stephanie Traub (Cancer Research UK; London, UK) discusses her work as a biomarker specialist and the challenges she faces when developing biomarker strategies.